Garcia-Manero G - Search Results

1

Immunotherapy in Acute Myeloid Leukemia: Where We Stand.

Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, Jabbour E, Ravandi F, Kadia T, Burguera AF, Romano A, Loscocco F, Visani G, Martinelli G, Kantarjian H, Curti A. Isidori A, et al. Front Oncol. 2021 May 10;11:656218. doi: 10.3389/fonc.2021.656218. eCollection 2021. Front Oncol. 2021. PMID: 34041025 Free PMC article. Review.

2

The hyper-CVAD regimen in adult acute lymphocytic leukemia.

Garcia-Manero G, Kantarjian HM. Garcia-Manero G, et al. Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi. doi: 10.1016/s0889-8588(05)70192-1. Hematol Oncol Clin North Am. 2000. PMID: 11147229 Review.

3

Salvage therapy for refractory or relapsed acute lymphocytic leukemia.

Garcia-Manero G, Thomas DA. Garcia-Manero G, et al. Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205. doi: 10.1016/s0889-8588(05)70204-5. Hematol Oncol Clin North Am. 2001. PMID: 11253606 Review.

4

Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Giles F, et al. Invest New Drugs. 2001;19(1):13-20. doi: 10.1023/a:1006432012394. Invest New Drugs. 2001. PMID: 11291829 Clinical Trial.

5

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.

Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Giles FJ, et al. Cancer. 2001 Jul 15;92(2):406-13. doi: 10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u. Cancer. 2001. PMID: 11466696

6

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.

Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Giles FJ, et al. J Clin Oncol. 2002 Feb 1;20(3):656-64. doi: 10.1200/JCO.2002.20.3.656. J Clin Oncol. 2002. PMID: 11821445 Clinical Trial.

7

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. O'Brien S, et al. Cancer. 2002 Apr 1;94(7):2024-32. doi: 10.1002/cncr.10436. Cancer. 2002. PMID: 11932905 Free article.

8

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Kantarjian HM, et al. Blood. 2002 May 15;99(10):3547-53. doi: 10.1182/blood.v99.10.3547. Blood. 2002. PMID: 11986206 Free article. Clinical Trial.

9

Current therapy of chronic myelogenous leukemia.

Garcia-Manero G, Talpaz M, Kantarjian HM. Garcia-Manero G, et al. Intern Med. 2002 Apr;41(4):254-64. doi: 10.2169/internalmedicine.41.254. Intern Med. 2002. PMID: 11993784 Free article. Review.

10

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.

Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Verstovsek S, et al. Cancer. 2002 May 1;94(9):2416-25. doi: 10.1002/cncr.10490. Cancer. 2002. PMID: 12015767 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,007 results

Search Page

Filters